Why biosimilars are being held back in the US

06-12-2013 Managing Intellectual PropertyComments (0)


At the time, the Congressional Budget Office estimated that biosimilars approved through the new pathway would generate savings of $25 billion during the period of 2009-2018. Yet, as of November 2013, no one has sought to use the abbreviated pathway to ...

Read more on Managing Intellectual Property

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top